Development of a Population-Based Newborn Screening Method for Severe Combined Immunodeficiency in Manitoba, Canada

The incidence of Severe Combined Immunodeficiency (SCID) in Manitoba, (1/15,000), is at least three to four times higher than the national average and that reported from other jurisdictions. It is overrepresented in two population groups: Mennonites (ZAP70 founder mutation) and First Nations of Nort...

Full description

Bibliographic Details
Published in:International Journal of Neonatal Screening
Main Authors: Thompson, J. Robert, Greenberg, Cheryl R., Dick, Andrew, Jilkina, Olga, Kwan, Luvinia, Rubin, Tamar S., Zelinski, Teresa, Schroeder, Marlis L., Van Caeseele, Paul
Format: Text
Language:English
Published: MDPI 2018
Subjects:
Article
Canada
First Nations
Online Access:http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7548909/
https://doi.org/10.3390/ijns4020019
Description
Summary:The incidence of Severe Combined Immunodeficiency (SCID) in Manitoba, (1/15,000), is at least three to four times higher than the national average and that reported from other jurisdictions. It is overrepresented in two population groups: Mennonites (ZAP70 founder mutation) and First Nations of Northern Cree ancestry (IKBKB founder mutation). We have previously demonstrated that in these two populations the most widely utilized T-cell receptor excision circle (TREC) assay is an ineffective newborn screening test to detect SCID as these patients have normal numbers of mature T-cells. We have developed a semi-automated, closed tube, high resolution DNA melting procedure to simultaneously genotype both of these mutations from the same newborn blood spot DNA extract used for the TREC assay. Parallel analysis of all newborn screening specimens utilizing both TREC analysis and the high-resolution DNA procedure should provide as complete ascertainment as possible of SCID in the Manitoba population.

Similar Items